High Expression of TMEM33 Predicts Poor Prognosis and Promotes Cell Proliferation in Cervical Cancer

Overview

Journal Front Genet

Date 2022 Jul 14

PMID 35832191

Authors

Hanxiang Chen

Xia Zhao

Yongqing Li

Shaoming Zhang

Yunshan Wang

Lili Wang

Wanshan Ma

Affiliations

Soon will be listed here.

Abstract

The prognosis of patients with advanced cervical cancer remains unsatisfactory. A study indicated that transmembrane protein 33 (TMEM33) was implicated in tumor recurrence, while its role in cervical cancer has not been elucidated. TMEM33 expression in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) was primarily screened in The Cancer Genome Atlas (TCGA), and further validated in Gene Expression Omnibus (GEO) database. The Kaplan-Meier plotter analysis and Cox regression were constructed to evaluate the prognostic value of TMEM33 in CESC. Functional enrichment analysis was performed with GO, KEGG and GSEA tools. CCK-8 assay and colony formation assay were performed to investigate the carcinogenesis role of TMEM33 in cervical cancer cell proliferation. TMEM33 expression was significantly elevated in CESC compared with normal tissues. High expression of TMEM33 was associated with poor prognostic clinical characteristics in CESC patients. KM-plotter analysis revealed that patients with increased TMEM33 had shorter overall survival (OS), progress free interval (PFI), and disease specific survival (DSS). Moreover, Multivariate Cox analysis confirmed that high TMEM33 expression was an independent risk factor for OS in patients with CESC. TMEM33 was associated with immune infiltrates, and its expression was correlated with tumorigenesis-related genes RNF4, OCIAD1, TMED5, DHX15, MED28 and LETM1. More importantly, knockdown of TMEM33 in cervical cancer cells decreased the expression of those genes and inhibited cell proliferation. Increased TMEM33 in cervical cancer can serve as an independent prognostic marker and might play a role in tumorigenesis by promoting cell proliferation.

Citing Articles

TBP activates DCBLD1 transcription to promote cell cycle progression in cervical cancer.

Shen Z, Li M, Zhu H, Song T Funct Integr Genomics. 2024; 24(6):221.

PMID: 39586885 DOI: 10.1007/s10142-024-01496-8.

Shang X, Wang H, Gu J, Zhao X, Zhang J, Sun B PeerJ. 2024; 12:e17842.

PMID: 39131609 PMC: 11313409. DOI: 10.7717/peerj.17842.

ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.

Ding X, Wan A, Qi X, Jiang K, Liu Z, Chen B Curr Gene Ther. 2024; 24(5):441-452.

PMID: 38441026 DOI: 10.2174/0115665232285216240228071244.

TMEM33 as a Prognostic Biomarker of Cervical Cancer and Its Correlation with Immune Infiltration.

Zhang H, Wang J, Yang J, He Q, Guan S, Qiao M Mediators Inflamm. 2023; 2023:5542181.

PMID: 37273452 PMC: 10239303. DOI: 10.1155/2023/5542181.

The Clinical and Biological Effects of Receptor Expression-Enhancing Protein 6 in Tongue Squamous Cell Carcinoma.

Tseng C, Hung C, Shu C, Lee C, Chen C, Kuo M Biomedicines. 2023; 11(5).

PMID: 37238941 PMC: 10215315. DOI: 10.3390/biomedicines11051270.

References

Cui X, Wang X, Zhou X, Jia J, Chen H, Zhao W . miR-106a Regulates Cell Proliferation and Autophagy by Targeting LKB1 in HPV-16-Associated Cervical Cancer. Mol Cancer Res. 2020; 18(8):1129-1141. DOI: 10.1158/1541-7786.MCR-19-1114. View

Gadducci A, Tana R, Cosio S, Cionini L . Treatment options in recurrent cervical cancer (Review). Oncol Lett. 2012; 1(1):3-11. PMC: 3436344. DOI: 10.3892/ol_00000001. View

Yang Z, Sun Q, Guo J, Wang S, Song G, Liu W . GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy. 2018; 15(4):668-685. PMC: 6526811. DOI: 10.1080/15548627.2018.1539590. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Vivian J, Rao A, Nothaft F, Ketchum C, Armstrong J, Novak A . Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017; 35(4):314-316. PMC: 5546205. DOI: 10.1038/nbt.3772. View

Chen H, Zhang Q, Qiao L, Fan X, Zhang W, Zhao W . Cdc6 contributes to abrogating the G1 checkpoint under hypoxic conditions in HPV E7 expressing cells. Sci Rep. 2017; 7(1):2927. PMC: 5462782. DOI: 10.1038/s41598-017-03060-w. View

Urade T, Yamamoto Y, Zhang X, Ku Y, Sakisaka T . Identification and characterization of TMEM33 as a reticulon-binding protein. Kobe J Med Sci. 2015; 60(3):E57-65. View

Fenech E, Lari F, Charles P, Fischer R, Laetitia-Thezenas M, Bagola K . Interaction mapping of endoplasmic reticulum ubiquitin ligases identifies modulators of innate immune signalling. Elife. 2020; 9. PMC: 7332293. DOI: 10.7554/eLife.57306. View

10.

Arhatte M, Gunaratne G, El Boustany C, Kuo I, Moro C, Duprat F . TMEM33 regulates intracellular calcium homeostasis in renal tubular epithelial cells. Nat Commun. 2019; 10(1):2024. PMC: 6497644. DOI: 10.1038/s41467-019-10045-y. View

11.

Sengupta S, Michener C, Escobar P, Belinson J, Ganapathi R . Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol. 2008; 109(2):226-33. DOI: 10.1016/j.ygyno.2007.12.024. View

12.

Xu H, Hu M, Liu M, An S, Guan K, Wang M . Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. Biomaterials. 2020; 235:119769. PMC: 7093100. DOI: 10.1016/j.biomaterials.2020.119769. View

13.

Zou H, Chen H, Liu S, Gan X . Identification of a novel circ_0018289/miR-183-5p/TMED5 regulatory network in cervical cancer development. World J Surg Oncol. 2021; 19(1):246. PMC: 8371901. DOI: 10.1186/s12957-021-02350-y. View

14.

Thomas J, Abed M, Heuberger J, Novak R, Zohar Y, Beltran Lopez A . RNF4-Dependent Oncogene Activation by Protein Stabilization. Cell Rep. 2016; 16(12):3388-3400. PMC: 5125238. DOI: 10.1016/j.celrep.2016.08.024. View

15.

Sindiani A, Alshdaifat E, Alkhatib A . Investigating Cervical Risk Factors that Lead to Cytological and Biopsy Examination. Med Arch. 2020; 74(4):294-297. PMC: 7520059. DOI: 10.5455/medarh.2020.74.294-297. View

16.

Savage A, Kurusamy S, Chen Y, Jiang Z, Chhabria K, MacDonald R . tmem33 is essential for VEGF-mediated endothelial calcium oscillations and angiogenesis. Nat Commun. 2019; 10(1):732. PMC: 6374405. DOI: 10.1038/s41467-019-08590-7. View

17.

Hsieh N, Huang C, Li C, Wang I, Lee M . MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells. J Cell Physiol. 2018; 234(7):11265-11275. DOI: 10.1002/jcp.27784. View

18.

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

19.

Liu F, Ma M, Gao A, Ma F, Ma G, Liu P . PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling SCAP stability. EMBO J. 2021; 40(22):e108065. PMC: 8591543. DOI: 10.15252/embj.2021108065. View

20.

Matsuo K, Machida H, Mandelbaum R, Konishi I, Mikami M . Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2018; 152(1):87-93. PMC: 7528458. DOI: 10.1016/j.ygyno.2018.10.026. View